https://doi.org/10.4266/kjccm.2017.00059 important to evaluate safety issues through a review of adverse events after ST during the use of ECMO. We reviewed and analyzed the clinical correlation of preoperative coagulation status and bleeding complications after ST during ECMO utilization in critically ill patients.
Materials and Methods
We retrospectively identified all patients who underwent 
1) ECMO protocol and routine care
We applied the ECMO protocol based on the Extracorporeal Life Support Organization guidelines [5] . The ECMO system consisted of a polymethylpentene fiber oxygenator system (QUADROX PLS; Maquet Inc., Hirrlingen, Germany) with simplified Bioline-coated circuits (Maquet Inc., Rastatt, Germany). All patients were supported with centrifugal pumps (Maquet Inc.), and were cannulated peripherally through the femoral artery and vein or internal jugular vein using the Seldinger technique. Patients received an initial unfractionated heparin (UFH) bolus of 50 units/kg body weight when the cannula was placed, and UFH was continuously infused during ECMO. Exceptionally, patients who have bleeding complications supported ECMO without anticoagulation therapy. Based on assessment by the attending physician and intensivist of the individual benefits and risks of the procedure, most patients on ECMO who were undergoing, or expected to undergo, a prolonged weaning process underwent the ST procedure.
2) Anticoagulation and tracheostomy protocol
Our anticoagulation protocol involved stopping the administration of intravenous UFH 4 hours before the planned tracheostomy. However, we did not stop heparin infusion in patients at high risk of a thromboembolic event. ST was performed at the bedside in the intensive care unit (ICU) under sedation with propofol and remifentanil. The patient's shoulders were elevated and the head extended (unless cervical disease or injury was present), thereby elevating the upper trachea. Sterile drapes were placed, creating a surgical window from the top of the larynx to the suprasternal notch. After administration of local anesthesia, a skin incision (2-3 cm) was made at two fingers' width from the upper sternal notch. Sharp dissection was then made to cut through the platysma muscle, with bleeding controlled by hemostats and electrocautery. Blunt dissection parallel to the long axis of the trachea was then used to separate the submuscular tissues until the thyroid isthmus was identified. The isthmus must be mobilized and a small incision made to create a space for the tracheostomy procedure. Blunt dissection was continued longitudinally through the pretracheal fascia, and the target tracheal ring (usually the third) was 
3) Outcome definition
Complications associated with the tracheostomy procedure were graded as either major or minor, and were followed up until either death or hospital discharge. Major complications were defined as any of the following:
procedure-related death, acute hypotension, tracheal wall injury, pneumothorax, major bleeding requiring surgical repair, and stoma infection. Minor complications included localized minor bleeding, which was defined as self- 
4) Statistical analysis
All statistical analyses were performed using R software version 3.0.1 (http://www.R-project.org). Continuous variables were described as medians and ranges (minimum to maximum) and compared using the nonparametric Wilcoxon rank sum test. Categorical variables were described as numbers (%) and compared using Fisher exact test or chi-squared test. All tests were two-sided, and P-values less than 0.050 were considered statistically significant.
Results

1) Baseline characteristics
Between April 1, 2012 and March 31, 2016, 38 patients underwent ST while on ECMO. Their median age was 59 years (range, 20 to 83 years), and 26 (68.4%) were male. Thirty-three patients (86.8%) were on venoveno (VV) ECMO; three (7.9%) were on venovenoarterial (VVA) ECMO; and two (5.3%) were on venoarterial (VA) ECMO. The main indication for ECMO was severe acute respiratory distress syndrome, which was present in 31 patients (81.6%). The main primary lung-related diagnosis was pneumonia, which was present in 13 patients 
2) Coagulation characteristics
The median values for hemoglobin, platelet count, INR, and aPTT before ST were 9.6 g/dl (range, 7.5 to 12. Table 2 ).
3) Complications
There were no ST procedure-related deaths or periprocedural thrombotic complications related to ECMO. Two patients (5.3%) suffered a major bleeding complication:
one patient on VV ECMO, and for whom the heparin infusion was stopped before ST, developed bleeding at the tracheostomy site, which required electrocauterization; the second patient, supported by VA ECMO and not ad- All other complications were classified as minor bleeding (n = 2, 5.3%) and were treated with local compression.
Regarding the incidence of major or minor bleeding, there was no significant difference found among three groups according to pre-tracheostomy heparin management (P = 0.723). The total bleeding incidence after ST in groups 1, 2, and 3 was 15.4%, 0%, and 13.3%, respectively (Table 3 ).
4) Clinical course and further outcomes
The successful rates of weaning off ECMO and 6-month survival were 65.8% and 44.7%, respectively.
The total durations of mechanical ventilation, ECMO support, and ICU/hospital length of stay are presented in 163 days], respectively, P = 0.013) (Figure 1 ). In addition, the median number of days ventilator-free [6] was sig- 
Discussion
Of the 38 patients who underwent ST while on ECMO, the overall rate of ST-related clinically relevant complications was 10.6% and the rate of major bleeding complications was 5.3%. Our results suggest that ST can be safely used by experienced operators on adult patients undergoing ECMO, with careful optimization of the coagulation status.
Utilization of ECMO in the awake patient in the ICU has gained widespread acceptance [2] . However, despite the inherent benefits, extubation during ECMO is possible only for some patients and under the control of experienced personnel. Camporota et al. [1] reported that very few centers extubated patients during ECMO (almost The most important clinical benefit of tracheostomy is to allow early physical therapy and active rehabilitation by avoiding sedation and paralytics. It also facilitates pulmonary toilet and early ventilator weaning, and intermittent mechanical ventilation to help prevent atelectasis, especially when the patient is fatigued after active rehabilitation [7, 8] . Despite the fact that tracheostomy is required in many patients supported by ECMO for respiratory support, almost 30% of ECMO centers never perform tracheostomy on patients with ECMO, in view of the increased risk of bleeding [1] .
Hemorrhage is a potential complication that can be significantly exacerbated by the use of anticoagulation which is required with ECMO, and may thus have a marked impact on the patient's further clinical course [3, 9] . The degree of bleeding may be increased either during or after tracheostomy in patients supported by ECMO, due to the activation of coagulation enzymes, or to platelet depletion or anticoagulant medication [10] .
The rates of major bleeding in our study are similar to those recorded in studies on ST in critically ill patients [11] [12] [13] . Costa et al. [13] reported major complications in 12.2% of 56 patients undergoing ST in the emergency department. Bleeding was the most frequent complication, although no deaths were related to the procedure.
Schmidt et al. [3] reported no fatal complications directly related to ST in patients supported by ECMO. In that study, bleeding was the most frequent complication of ST and no significant difference was noted regarding the type of anticoagulation management, e.g., heparin cessation or maintenance. It remains to be established whether the use of anticoagulation increases the incidence of bleeding during tracheostomy in patients on ECMO. Pasin et al. [14] reported a minor bleeding incidence of 19% for tracheostomy, and an incidence of 6% for major bleeding requiring that transfusion patients be administered anticoagulation. However, in our experience, bleeding complications were not seen in the group administered heparin. This finding may be related to the fact that, in our patients in the heparin group, the therapeutic levels were maintained well by following a low-dose anticoagulation protocol. Previously, we reported that the low-dose heparin strategy is a safe and effective protocol to reduce bleeding in adults undergoing ECMO [15] . Therefore, for the safe performance of tracheostomy, we recommend the use of low-dose heparin during ECMO and for stopping the administration of intravenous UFH 4 hours before the planned tracheostomy. Heparin administration,
at the previous rate, should be initiated within 2 hours of completion of the tracheostomy, and adjusted according to subsequent coagulation test results. Exceptionally, in a patient at high risk of a thromboembolic event, ST can be performed while anticoagulation therapy is administered.
In such a case, the surgeon(s) must be skilled in performing proper and accurate hemostasis to prevent postoperative bleeding.
Recently, percutaneous dilatational tracheostomy (PDT) has replaced ST in many ICUs, with comparable safety and convenience in the hands of the experienced operator [16, 17] . Although PDT is more accessible and less timedemanding compared to ST, it has several weaknesses [18] [19] [20] [21] . PDT is associated with a high risk of both morbidity and mortality in certain patients, and includes the requirement for high positive end-expiratory pressure or fraction of inspired oxygen (FiO 2 ), difficult anatomy (e.g., obesity, thick short neck, or tracheal deviation), coagulopathy, emergency procedures, and hemodynamic instability [22, 23] . The need for better visualization of local neck anatomy and improved control of oxygenic/ hemodynamic stability establishes ST as the safest method in critical situations such as ECMO. Although the bleeding incidence is comparable in ST and PDT, the former method is more effective in the prevention and control of bleeding complications [19, 24] . Several recent reports have been published on the safety of thoracic surgical procedures involving ECMO, but none to date on the safety aspects of ST in patients supported by ECMO [25, 26] . In our experience there were minimal complications, which was easily corrected. ST was well tolerated and enhanced the delivery of care in the period prior to lung recovery.
This study has several limitations. The interpretation of the result is limited by potential bias introduced by the retrospective study design. The available data are limited to those recorded in the medical record, which may have been missed or underestimated. However, we recorded all severe complications, and these were detected by the detailed review. In addition, the small sample size reduces the power of this study. Therefore, further larger studies are needed to confirm these preliminary results and bleeding risk stratification for scheduled ST in patients supported by ECMO.
In conclusion, the complication rates of ST in patients supported by ECMO were low and comparable to 
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